GlassScriptPhysician profile
Brock Spencer Harding
NPI 1790348811
$849.50
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $398 · 2024: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $849.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $320.17 | 2023-2024 | |
| Novartis Pharmaceuticals Corporation | $151.42 | 2023-2024 | |
| Lilly USA, LLC | $102.09 | 2023-2024 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $71.10 | 2024 | Rybelsus, Ozempic |
| Phathom Pharmaceuticals, INC. | $52.58 | 2024 | Voquezna |
| Abbott Laboratories | $45.20 | 2023-2024 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $29.24 | 2024 | Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $18.48 | 2024 | Trintellix |
| Exact Sciences Corporation | $16.44 | 2023 | Cologuard Collection Kit |
| Pfizer INC. | $15.78 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.54 | 2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.46 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brock Harding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.